Orally administered penicillamine is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts.

[1]  R. Ian Freshney,et al.  Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications , 2010 .

[2]  A. Mandinova,et al.  Inhibition of in-stent restenosis by oral copper chelation in porcine coronary arteries. , 2006, American journal of physiology. Heart and circulatory physiology.

[3]  G. Angelini,et al.  Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? , 2006, Atherosclerosis.

[4]  G. Angelini,et al.  Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation and superoxide formation in the aorta of the rabbit. , 2006, European journal of pharmacology.

[5]  G. Angelini,et al.  Calcium and the replication of human vascular smooth muscle cells: studies on the activation and translocation of extracellular signal regulated kinase (ERK) and cyclin D1 expression. , 2005, European journal of pharmacology.

[6]  G. Angelini,et al.  Reactive oxygen species, vascular disease and cardiovascular surgery. , 2004, Current vascular pharmacology.

[7]  G. Angelini,et al.  The endothelin 1A receptor antagonist BSF 302146 is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. , 2004, The Journal of thoracic and cardiovascular surgery.

[8]  Yung-Hyun Choi,et al.  PDTC, metal chelating compound, induces G1 phase cell cycle arrest in vascular smooth muscle cells through inducing p21Cip1 expression: Involvement of p38 mitogen activated protein kinase , 2004, Journal of cellular physiology.

[9]  Richard W. Martin,et al.  High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. , 2004, Seminars in arthritis and rheumatism.

[10]  S. Merajver,et al.  Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. , 2003, Molecular cancer research : MCR.

[11]  R. Soldi,et al.  Copper chelation represses the vascular response to injury , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Brewer.  Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation , 2003, Journal of cellular and molecular medicine.

[13]  G. Angelini,et al.  Sustained increases of plasma homocysteine, copper, and serum ceruloplasmin after coronary artery bypass grafting. , 2002, The Annals of thoracic surgery.

[14]  V. Culotta,et al.  Copper Chaperones: Personal Escorts for Metal Ions , 2002, Journal of bioenergetics and biomembranes.

[15]  M. Won,et al.  Oxidative modification of human ceruloplasmin by peroxyl radicals. , 2001, Biochimica et biophysica acta.

[16]  M. Burkitt.  A critical overview of the chemistry of copper-dependent low density lipoprotein oxidation: roles of lipid hydroperoxides, alpha-tocopherol, thiols, and ceruloplasmin. , 2001, Archives of biochemistry and biophysics.

[17]  G. Angelini,et al.  Oxidative Stress, Nitric Oxide, and Vascular Disease , 2001, Journal of cardiac surgery.

[18]  L. Campeau.  Lipid lowering and coronary bypass graft surgery , 2000, Current opinion in cardiology.

[19]  B. Mazumder,et al.  Ceruloplasmin and cardiovascular disease. , 2000, Free radical biology & medicine.

[20]  S. Choi,et al.  Fragmentation of human ceruloplasmin induced by hydrogen peroxide. , 2000, Biochimie.

[21]  D. McMillin,et al.  On the lability and functional significance of the type 1 copper pool in ceruloplasmin , 1999, JBIC Journal of Biological Inorganic Chemistry.

[22]  H. Daida,et al.  [Elevated levels of plasma homocysteine related to saphenous vein graft disease after coronary artery bypass graft surgery]. , 1998, Journal of cardiology.

[23]  A. Mitchell,et al.  Copper, lysyl oxidase, and extracellular matrix protein cross-linking. , 1998, The American journal of clinical nutrition.

[24]  R. Favaloro,et al.  Critical analysis of coronary artery bypass graft surgery: a 30-year journey. , 1998, Journal of the American College of Cardiology.

[25]  E J Topol,et al.  Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.

[26]  B. Hultberg,et al.  The cell-damaging effects of low amounts of homocysteine and copper ions in human cell line cultures are caused by oxidative stress. , 1997, Toxicology.

[27]  G. Breithardt,et al.  Copper-induced inflammatory reactions of rat carotid arteries mimic restenosis/arteriosclerosis-like neointima formation. , 1997, Atherosclerosis.

[28]  Y. Wilson,et al.  Hyperhomocysteinaemia is a risk factor for vein graft stenosis. , 1996, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[29]  W J Keon,et al.  Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. , 1996, Journal of the American College of Cardiology.

[30]  T. Ogihara,et al.  Plasma Copper and Antioxidant Status in Wilson's Disease , 1995, Pediatric Research.

[31]  M. Davies,et al.  Pathobiology of intimal hyperplasia , 1994, The British journal of surgery.

[32]  B. Portmann,et al.  Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease , 1992, Hepatology.

[33]  A. Newby,et al.  Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. , 2005, Physiological reviews.

[34]  G. Angelini,et al.  Oxidant stress, nitric oxide and vascular disease , 2002 .

[35]  F. Castellino,et al.  Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. , 2001, The American journal of pathology.

[36]  G. Angelini,et al.  The endothelin(A) (ETA) receptor antagonist, BSF 302146, is a potent inhibitor of porcine vein graft thickening, in vivo , 2000 .